US 11,944,675 B2
Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
Fabiana Fernandez, Unterengstringen (CH); Michael Kowarik, Zurich (CH); Michael Wacker, Unterengstringen (CH); and Michael Wetter, Zurich (CH)
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed on Oct. 2, 2020, as Appl. No. 17/061,687.
Application 17/061,687 is a continuation of application No. 14/522,254, filed on Oct. 23, 2014, granted, now 10,835,592.
Application 14/522,254 is a continuation of application No. 12/735,773, granted, now 8,895,014, issued on Nov. 25, 2014, previously published as PCT/IB2009/000287, filed on Feb. 19, 2009.
Claims priority of provisional application 61/136,687, filed on Sep. 25, 2008.
Claims priority of provisional application 61/129,852, filed on Jul. 24, 2008.
Claims priority of provisional application 61/129,480, filed on Jun. 30, 2008.
Claims priority of provisional application 61/071,545, filed on May 5, 2008.
Claims priority of provisional application 61/064,163, filed on Feb. 20, 2008.
Prior Publication US 2021/0085772 A1, Mar. 25, 2021
Int. Cl. A61K 39/112 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 39/104 (2006.01); A61K 39/108 (2006.01); A61K 39/385 (2006.01); C07K 14/195 (2006.01)
CPC A61K 39/0283 (2013.01) [A61K 39/0258 (2013.01); A61K 39/104 (2013.01); A61K 39/105 (2013.01); A61K 39/385 (2013.01); C07K 14/195 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6068 (2013.01); A61K 2039/6087 (2013.01); C07K 2319/034 (2013.01); Y02A 50/30 (2018.01)] 7 Claims
 
1. A bioconjugate vaccine comprising:
(i) a protein carrier, which is a modified, genetically detoxified Exotoxin of Pseudomonas aeruginosa (EPA), comprising at least two[[ ]] inserted consensus sequences, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline[[ ]]; and
(ii) at least one antigenic polysaccharide from at least one bacterium, N-linked to the protein carrier by attachment of the antigenic polysaccharide to the asparagine residue of the D/E-X-N-Z-S/T consensus sequence, wherein the at least one antigenic polysaccharide is a bacterial 0-antigen from one or more strain of Shigella, Escherichia coli (E. coli) or Pseudomonas aeruginosa; and,
optionally, an adjuvant.